Abstracts tagged "gout"

Abstract Number: 1184 • ACR Convergence 2021
Voluntary Online Gout Module: Housestaff Utilization and Efficacy
Sarah Tarplin¹, Susan Kroop² and Catherine Deffendall², ¹Vanderbilt Universty Medical Center, nashville, TN, ²Vanderbilt University, Nashville, TN
Background/Purpose: All Internal Medicine (IM) physicians should be competent in gout diagnosis and management. The purpose of this study is to assess learner engagement with…
Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
Abstract Number: 0672 • ACR Convergence 2021
Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years
Chio Yokose¹, Natalie McCormick², Na Lu³, Amit Joshi² and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…
Abstract Number: 1449 • ACR Convergence 2021
Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?
Sarah Stewart¹, Amanda Phipps-Green², Gregory Gamble¹, Lisa Stamp³, William Taylor⁴, Tuhina Neogi⁵, Tony Merriman⁶ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago Dunedin, Dunedin, New Zealand, ³University of Otago, Christchurch, Christchurch, New Zealand, ⁴University of Otago Wellington, Auckland, New Zealand, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: Elevated serum urate is the most important risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
Abstract Number: 0177 • ACR Convergence 2021
Dual-Energy Computed Tomography Three Material Decomposition Improves the Sensitivity of Gout Detection
Justin Tse¹, Douglas Kondro², Yves Pauchard³, Andrea Veljkovic⁴, Viviane Frasson⁵, David Holdsworth⁶, Sarah Manske⁷, Paul MacMullan⁸ and Peter Salat⁷, ¹UNIVERSITY OF CALGARY, Calgary, AB, Canada, ²STEMCELL Technologies, Cambridge, United Kingdom, ³Department of Electrical and Software Engineering, Schulich School of Engineering, Calgary, AB, Canada, ⁴University of British Columbia, Department of Orthopaedics, Vancouver, BC, Canada, ⁵University of Calgary, Human Performance Lab, Calgary, AB, Canada, ⁶University of Western Ontario, Department of Surgery, London, ON, Canada, ⁷University of Calgary, Department of Radiology, Calgary, AB, Canada, ⁸University of Calgary, Department of Rheumatology, Calgary, AB, Canada
Background/Purpose: Gout, a curable musculoskeletal disease, is characterized by the deposition and accumulation of monosodium urate (MSU) crystals within affected joints. Dual-energy computed tomography (DECT),…
Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Jasvinder Singh¹, Kenneth Saag¹, Joshua Baker², Amy Joseph³, Seth Eisen⁴ and Terence Shaneyfelt¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Washington University / St. Louis VA, St Louis, MO, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…
Abstract Number: 1565 • ACR Convergence 2021
Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial
Kazuki Yoshida¹, Robert J. Glynn¹, Hyon K. Choi², Brendan M. Everett¹, Yi Li³, Jean G. MacFadyen¹, Paul M. Ridker¹ and DH Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Previous analyses in the CANTOS trial demonstrated a benefit of canakinumab (CAN; IL-1β inhibitor) on gout flares. We aimed to quantify the mediating role…
Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
James O'Dell¹, Tuhina Neogi², Michael Pillinger³, Paul Palevsky⁴, Jeff Newcomb¹, Mary Brophy⁵, Hongsheng Wu⁵, Annie Davis-Karim⁶, Ryan Ferguson⁵, David Pittman⁶, Robert Terkeltaub⁷, Amy Cannella¹, Bryant England¹, Lindsay Helget¹, Ted Mikuls¹ and Tomas Taylor⁸, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³New York University Grossman School of Medicine, New York,, NY, ⁴Pittsburgh University, Pittsburgh, PA, ⁵Boston VA, Boston, MA, ⁶Albuquerque VA, Albuquerque, NM, ⁷VA/UCSD, San Diego, CA, ⁸White River Junction VA, White River Junction, VT
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
Abstract Number: 0467 • ACR Convergence 2021
Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)
Michael Toprover¹, Michael Mechlin¹, Anastasia Slobodnick¹, Virginia Pike¹, Cheongeun Oh¹, Claudine Davis¹, Theodore Fields², Fabio Becce³ and Michael Pillinger⁴, ¹NYU Langone Health, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Axial gout involvement was first reported in 1950 (1). Over 100 cases have subsequently been published. Reported cases have presented as acute back pain,…
Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Anushree Tiku¹, Neil Boudville², Fiona Brown³, Alan Cass⁴, Phiilip Clarke⁵, Richard Day⁶, Janak de Zoysa⁷, Bettina Douglas⁸, Randall Faull⁹, David Harris¹⁰, Carmel Hawley¹¹, Graham Jones⁶, John Kanellis³, Elaine Pascoe¹¹, Suetonia Palmer¹², Vlado Perkovic¹³, Gopala Rangan¹⁰, Donna Reidlinger¹¹, Laura Robison¹¹, Robert Walker¹⁴, Giles Walters¹⁵, David Johnson¹¹, Sunil Badve¹³ and Nicola Dalbeth⁷, ¹The George Institute of Australia, Sydney, Australia, ²University of Western Australia, Perth, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies School of Health Research, Darwin, Australia, ⁵University of Oxford, Oxford, United Kingdom, ⁶University of New South Wales, Sydney, Australia, ⁷University of Auckland, Auckland, New Zealand, ⁸Princess Alexandra Hospital, Brisbane, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰University of Sydney, Sydney, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²University of Otago, Christchurch, New Zealand, ¹³The George Institute for Global Health, Sydney, Australia, ¹⁴University of Otago, Dunedin, New Zealand, ¹⁵The Canberra Hospital, Canberra, Australia
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…
Abstract Number: 1567 • ACR Convergence 2021
Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients
Luigi Brunetti¹, Lujing Wang², Andrew Wassef², Anita Brinker³, Brian T Buckley⁴, Peter Lipsky⁵, Ah-Ng Kong² and Naomi Schlesinger⁶, ¹Rutgers The State University of New Jersey, Piscataway, NJ, ²Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, ³Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey,, Piscataway, NJ, ⁴Environmental and Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ, ⁵AMPEL BioSolutions, Charlottesville, VA, ⁶Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Tart cherries (TC) contain high levels of anthocyanins that exert potent antioxidant and anti-inflammatory effects. Approximately 50% of gout patients report using TC to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].